G Saglio
Overview
Explore the profile of G Saglio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
4763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bucelli C, Capodanno I, Miggiano M, Cavazzini F, Crescenzi S, Russo S, et al.
Eur J Haematol
. 2024 Sep;
114(1):37-44.
PMID: 39263855
Objectives: The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP-CML patients. Methods: A retrospective analysis was conducted on 332 CP-CML patients...
2.
Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano M, Binotto G, et al.
Front Pharmacol
. 2023 Apr;
14:1154377.
PMID: 37033642
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However,...
3.
Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F, et al.
Leukemia
. 2020 Mar;
34(4):966-984.
PMID: 32127639
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal...
4.
Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al.
Leukemia
. 2017 Jun;
32(2):413-418.
PMID: 28607470
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine...
5.
Pellegrino R, Riondato F, Ferbo L, Boero M, Palmieri A, Osella L, et al.
Biomed Res Int
. 2017 May;
2017():2408941.
PMID: 28540293
Type 3 haemochromatosis (HFE3) is a rare genetic iron overload disease which ultimately lead to compromised organs functioning. HFE3 is caused by mutations in transferrin receptor 2 (TFR2) gene that...
6.
Hochhaus A, Masszi T, Giles F, Radich J, Ross D, Gomez Casares M, et al.
Leukemia
. 2017 Feb;
31(7):1525-1531.
PMID: 28218239
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with...
7.
Foa R, Tassinari A, Fierro M, Raspadori D, Resegotti L, Degani G, et al.
Leuk Lymphoma
. 2016 Jul;
2(1-2):103-10.
PMID: 27456577
In fourteen patients with hairy cell leukemia (HCL) the configuration of the immunoglobulin (Ig) heavy chain genes was used as a marker of clonality, to monitor the response of the...
8.
Saglio G
Leuk Suppl
. 2016 May;
1(Suppl 2):S40-2.
PMID: 27175246
Impressive response rates and good tolerability have led imatinib 400 mg once a day to become the standard frontline therapy for chronic myeloid leukemia (CML) patients. However, approximately one-third of...
9.
Cross N, White H, Ernst T, Welden L, Dietz C, Saglio G, et al.
Leukemia
. 2016 Apr;
30(9):1844-52.
PMID: 27109508
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most...
10.
Hochhaus A, Saglio G, Hughes T, Larson R, Kim D, Issaragrisil S, et al.
Leukemia
. 2016 Feb;
30(5):1044-54.
PMID: 26837842
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression...